Navigation auf uzh.ch
Navigation auf uzh.ch
Acylcarnitines have important roles in energy metabolism and hold promise as novel biomarkers for adverse cardiovascular outcomes. In a multinational effort, Drs. Allan Davies & Florian A. Wenzl and colleagues studied the relationship of circulating acylcarnitines and major adverse cardiovascular events (MACE) in patients presenting with acute coronary syndromes (ACS).
The study group found that acylcarnitines predict residual cardiovascular risk beyond established risk factors and represent novel biomarkers in patients with ACS. Learn more about the full study results here.
